| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3030690 | Trends in Cardiovascular Medicine | 2010 | 5 Pages |
Abstract
Recent experimental data suggest glucagon-like peptide 1 (GLP-1) and its analogs to have direct effects on the cardiovascular system, in addition to their classic glucoregulatory actions. These direct effects may be cardioprotective, contractility augmenting, and vasorelaxant. A few preliminary clinical trials appear to support a mechanical function improvement after GLP-1 administration to patients with a weakened left ventricle. Based on animal studies, diminished lethal injury to the postischemic reperfused myocardium appears to be a particularly promising prospect, awaiting to be tested in clinical settings.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Marek Treiman, Mikkel Elvekjær, Thomas Engstrøm, Jan Skov Jensen,